Zenas BioPharma (NASDAQ:ZBIO) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Zenas BioPharma (NASDAQ:ZBIO) from a hold rating to a sell rating in a research report report published on Friday.

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $20.09 on Friday. Zenas BioPharma has a 52-week low of $5.83 and a 52-week high of $26.25. The company has a 50-day simple moving average of $17.34 and a two-hundred day simple moving average of $12.46. The company has a market capitalization of $845.99 million and a price-to-earnings ratio of -5.66.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.23).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ZBIO. Nuveen LLC bought a new stake in shares of Zenas BioPharma in the 1st quarter worth approximately $250,000. New York State Common Retirement Fund bought a new position in Zenas BioPharma during the first quarter valued at $49,000. Jefferies Financial Group Inc. purchased a new stake in Zenas BioPharma in the first quarter worth $348,000. Geode Capital Management LLC raised its stake in shares of Zenas BioPharma by 4.6% in the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after buying an additional 8,207 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.